Fred Alger Management’s TG Therapeutics TGTX Stock Holding History

Fred Alger Management’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.93M	Buy	35,165 +16,577	+89%	+$678K	0.01%	322
2026 Q1	$617K	Buy	+18,588	New	+$554K	﹤0.01%	372
2025 Q3	–	Sell	-88,198	Closed	-$2.76M	–	497
2025 Q2	$2.76M	Buy	+88,198	New	+$3.28M	0.01%	293
2021 Q3	–	Sell	-72,209	Closed	-$2.8M	–	559
2021 Q2	$2.8M	Sell	72,209 -3,094	-4%	-$122K	0.01%	335
2021 Q1	$3.63M	Sell	75,303 -11,749	-13%	-$564K	0.01%	313
2020 Q4	$4.53M	Buy	87,052 +20,778	+31%	+$702K	0.01%	284
2020 Q3	$1.77M	Sell	66,274 -8,726	-12%	-$201K	0.01%	312
2020 Q2	$1.46M	Buy	75,000 +34,000	+83%	+$548K	﹤0.01%	325
2020 Q1	$403K	Buy	+41,000	New	+$518K	﹤0.01%	369
2016 Q4	–	Sell	-70,000	Closed	-$542K	–	523
2016 Q3	$542K	Buy	70,000 +1,900	+3%	+$12.2K	﹤0.01%	350
2016 Q2	$413K	Hold	68,100	–	–	﹤0.01%	387
2016 Q1	$580K	Sell	68,100 -12,350	-15%	-$108K	﹤0.01%	408
2015 Q4	$960K	Hold	80,450	–	–	﹤0.01%	387
2015 Q3	$811K	Hold	80,450	–	–	﹤0.01%	398
2015 Q2	$1.33M	Buy	80,450 +7,450	+10%	+$118K	0.01%	410
2015 Q1	$1.13M	Buy	+73,000	New	+$1.11M	0.01%	489

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Fred Alger Management's TGTX Position: Q2 2026 in Review

Fred Alger Management increased its TG Therapeutics (TGTX) stake by 89% in Q2 2026, buying an estimated $678K and bringing the position to 35,165 shares worth $1.93M. The position accounts for 0.01% of the portfolio, ranked #322.

Fred Alger Management first reported a position in TGTX in Q1 2015 and has held it in 16 quarters since. The position peaked at $4.53M in Q4 2020. 428 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

Fred Alger Management held 35,165 shares of TG Therapeutics worth $1.93M as of Q2 2026.
Fred Alger Management bought 16,577 TG Therapeutics shares in Q2 2026, an estimated $678K.
TG Therapeutics made up 0.01% of Fred Alger Management's portfolio in Q2 2026, its #322 holding.
Fred Alger Management first reported a position in TG Therapeutics in Q1 2015 and has held it in 16 quarters since.
Fred Alger Management's TG Therapeutics position peaked at $4.53M in Q4 2020.
428 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Fred Alger Management's 13F filing for Q2 2026, filed 14 Aug 2026.